MedTrace Logo

Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

NCT02120196 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-09

No results posted yet for this study

Summary

The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.

Conditions

Interventions

DRUG

Rifaximin

rifaximin 1200 mg daily versus norfloxacin 400 mg once daily

DRUG

Norfloxacin

FDA approved:400mg once daily

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Asem A Elfert · TUH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02120196 on ClinicalTrials.gov